Pin Wang, PhD

Professor

Image of Pin Wang, PhD
Is this your profile? Click to edit

Overview

The Wang laboratory focuses on an emerging field of “immunobioengineering” with the aim of employing engineering tools and principles to quantitatively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses. The ongoing research research projects include: 1) exploring various strategies to engineer virus-derived vector systems for dendritic cell-targeted vaccine delivery and oncolytic virus-based immunotherapy; 2) designing and optimizing cellular immunotherapy that is based on molecular engineering of chimeric antigen receptors (CARs); 3) exploring immune cells as drug carriers for targeted delivery of immunomodulatory drugs to enhance cancer immunotherapy; 4) exploring systems biology tools for modeling and understanding details of signaling pathways mediated by designer molecules such as chimeric antigen receptors to activate T cells; 5) developing engineering methods to improve adeno-associated virus (AAV)-based gene delivery. In this research laboratory, bioengineers collaborate with chemists, immunologists, computer scientists, and system biologists to directly address problems in translational immunology and develop and optimize innovative approaches to improve lives of patients suffering from cancer and infectious diseases.

Research Funding

  • In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
    NIH · R01EB017206 · Sep 1, 2013 – Aug 31, 2020 · Role: Co-Principal Investigator
  • SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)
    NIH · R01CA170820 · Sep 17, 2012 – Jun 30, 2017 · Role: Co-Principal Investigator
  • Targeting lentiviruses to infect chosen cells
    NIH · R01AI068978 · Feb 1, 2006 – Jan 31, 2012 · Role: Principal Investigator

Research Keywords

  • Cancer Immunotherapy
  • Immunoengineering
  • T Cell Engineering
  • Chimeric Antigen Receptor
  • Cancer Vaccine
  • Gene Therapy
  • Immuno-Oncology

Publications

  • Serum stable natural peptides designed by mRNA display. Sci Rep. 2014 Sep 19; 4:6008.. View in PubMed
  • Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm. 2014 May 05; 11(5):1651-61.. View in PubMed
  • Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides. Mol Ther Methods Clin Dev. 2014; 1:12.. View in PubMed
  • Passive immunization against HIV/AIDS by antibody gene transfer. Viruses. 2014 Jan 27; 6(2):428-47.. View in PubMed
  • Visualization of intracellular pathways of engineered baculovirus in mammalian cells. Virus Res. 2014 Mar 06; 181:81-91.. View in PubMed
  • Advances and challenges in the use of nanoparticles to optimize PK/PD interactions of combined anti-cancer therapies. Curr Drug Metab. 2014; 15(8):818-28.. View in PubMed
  • Synthetic niches for differentiation of human embryonic stem cells bypassing embryoid body formation. J Biomed Mater Res B Appl Biomater. 2014 Jul; 102(5):1101-12.. View in PubMed
  • Visualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cells. PLoS One. 2013; 8(6):e67400.. View in PubMed
  • A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells. J Vis Exp. 2013 Jun 19.. View in PubMed
  • Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. Biomed Res Int. 2013; 2013:378380.. View in PubMed